[go: up one dir, main page]

WO2011147026A3 - Préparation pharmaceutique stable contenant du telmisartan et de l'hydrochlorothiazide - Google Patents

Préparation pharmaceutique stable contenant du telmisartan et de l'hydrochlorothiazide Download PDF

Info

Publication number
WO2011147026A3
WO2011147026A3 PCT/CA2011/000621 CA2011000621W WO2011147026A3 WO 2011147026 A3 WO2011147026 A3 WO 2011147026A3 CA 2011000621 W CA2011000621 W CA 2011000621W WO 2011147026 A3 WO2011147026 A3 WO 2011147026A3
Authority
WO
WIPO (PCT)
Prior art keywords
telmisartan
pharmaceutical formulation
stable pharmaceutical
weight
hydrochlorothiazide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2011/000621
Other languages
English (en)
Other versions
WO2011147026A2 (fr
Inventor
Naresh Talwar
Dean Sebastian
Mathew Philip
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmascience Inc
Original Assignee
Pharmascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmascience Inc filed Critical Pharmascience Inc
Priority to CA2801020A priority Critical patent/CA2801020A1/fr
Publication of WO2011147026A2 publication Critical patent/WO2011147026A2/fr
Publication of WO2011147026A3 publication Critical patent/WO2011147026A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une préparation pharmaceutique stable contenant du telmisartan, ou un sel pharmaceutiquement acceptable de celui-ci, et un diurétique dispersé dans une matrice. La matrice contient au moins un délitant dans une quantité comprise entre 0,5 % et 20% en poids ; un agent d'amélioration de dissolution présent dans un rapport molaire agent d'amélioration de dissolution - telmisartan compris entre 1:1 et 10:1 ; et un diluant hydro-insoluble dans une quantité comprise entre 15% et 75% en poids et au moins un autre excipient ou adjuvant pharmaceutiquement acceptable dans une quantité comprise entre 0 et 25% en poids.
PCT/CA2011/000621 2010-05-28 2011-05-27 Préparation pharmaceutique stable contenant du telmisartan et de l'hydrochlorothiazide Ceased WO2011147026A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2801020A CA2801020A1 (fr) 2010-05-28 2011-05-27 Preparation pharmaceutique stable contenant du telmisartan et de l'hydrochlorothiazide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2,706,292 2010-05-28
CA2706292A CA2706292A1 (fr) 2010-05-28 2010-05-28 Une formulation pharmaceutique stable renfermant du telmisartan et de l'hydrochlorothiazide

Publications (2)

Publication Number Publication Date
WO2011147026A2 WO2011147026A2 (fr) 2011-12-01
WO2011147026A3 true WO2011147026A3 (fr) 2012-01-26

Family

ID=45004457

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2011/000621 Ceased WO2011147026A2 (fr) 2010-05-28 2011-05-27 Préparation pharmaceutique stable contenant du telmisartan et de l'hydrochlorothiazide

Country Status (2)

Country Link
CA (2) CA2706292A1 (fr)
WO (1) WO2011147026A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102885789A (zh) * 2012-04-05 2013-01-23 常州制药厂有限公司 一种治疗高血压的复方制剂的制备方法
WO2014068507A1 (fr) * 2012-11-02 2014-05-08 Abbott Healthcare Pvt. Ltd. Compositions pharmaceutiques orales solides de telmisartan essentiellement exemptes de tensioactifs
EP3389652B1 (fr) 2015-12-14 2022-09-28 X4 Pharmaceuticals, Inc. Méthodes de traitement du cancer
US10953003B2 (en) 2015-12-14 2021-03-23 X4 Pharmaceuticals, Inc. Methods for treating cancer
ES2935834T3 (es) 2015-12-22 2023-03-10 X4 Pharmaceuticals Inc Métodos para tratar enfermedad de inmunodeficiencia
US20190030023A1 (en) * 2016-01-22 2019-01-31 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3019394A1 (fr) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methodes de traitement du cancer
WO2017223243A1 (fr) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Inhibiteurs de cxcr4 et leurs utilisations
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
CN109562106B (zh) 2016-06-21 2023-03-21 X4 制药有限公司 Cxcr4抑制剂及其用途
CN107501192A (zh) * 2017-08-15 2017-12-22 中国科学院上海药物研究所 替米沙坦与氢氯噻嗪的共晶
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
EP4117662A4 (fr) 2020-03-10 2024-04-03 X4 Pharmaceuticals, Inc. Méthodes de traitement de la neutropénie

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004028505A1 (fr) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Formulations pharmaceutiques sous forme solide contenant du telmisartan
CA2524091A1 (fr) * 2003-04-30 2004-11-11 Boehringer Ingelheim International Gmbh Formulation pharmaceutique du sel de sodium telmisartan
CA2644179A1 (fr) * 2007-11-21 2009-05-21 Pharmascience Inc. Composition pharmaceutique inedite comprenant une matrice de desintegration
WO2011025467A1 (fr) * 2009-08-24 2011-03-03 Bilgic Mahmut Formes posologiques solides comprenant du telmisartan

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004028505A1 (fr) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Formulations pharmaceutiques sous forme solide contenant du telmisartan
CA2524091A1 (fr) * 2003-04-30 2004-11-11 Boehringer Ingelheim International Gmbh Formulation pharmaceutique du sel de sodium telmisartan
CA2644179A1 (fr) * 2007-11-21 2009-05-21 Pharmascience Inc. Composition pharmaceutique inedite comprenant une matrice de desintegration
WO2011025467A1 (fr) * 2009-08-24 2011-03-03 Bilgic Mahmut Formes posologiques solides comprenant du telmisartan

Also Published As

Publication number Publication date
WO2011147026A2 (fr) 2011-12-01
CA2706292A1 (fr) 2011-11-28
CA2801020A1 (fr) 2011-12-01

Similar Documents

Publication Publication Date Title
WO2011147026A3 (fr) Préparation pharmaceutique stable contenant du telmisartan et de l'hydrochlorothiazide
WO2008148742A3 (fr) Préparation pharmaceutique pour produire des comprimés à délitement rapide
AR041370A1 (es) Formulaciones farmaceuticas solidas que comprenden telmisartano y su preparacion
RU2015124694A (ru) Саморегулируемое высвобождение фармацевтического ингредиента
WO2007093425A3 (fr) Forme d'administration par voie orale stable au stockage d'amoxicilline et d'acide clavulanique
MX2013002377A (es) Forma de dosificacion resistente a manipulacion que comprende una sal inorganica.
HK1200742A1 (en) Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer
WO2011115969A3 (fr) Procédé de fabrication d'une forme posologique multiphasique à dissolution rapide, lyophilisée
SI2729130T1 (en) Combined formulations of darunavir
NZ600231A (en) Pharmaceutical compositions comprising sigma receptor ligands
AR075039A1 (es) Formulacion farmaceutica o alimentaria de liberacion controlada y procedimiento para su preparacion
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2011112922A3 (fr) Co-cristaux et formulations pharmaceutiques comprenant ceux-ci
HRP20160327T1 (hr) Čvrsti dozirni oblici fentanila s poboljšanom bukalnom apsorpcijom
WO2011019326A3 (fr) Formulation pharmaceutique permettant d'augmenter la solubilité et la stabilité
WO2007071581A3 (fr) Formulation pharmaceutique destinee a la fabrication de comprimes a desintegration rapide
WO2008116601A3 (fr) Formes galéniques solides comprenant de l'aliskiren et ses sels pharmaceutiquement acceptables
WO2012087255A3 (fr) Formulations pharmaceutiques
WO2012085284A3 (fr) Formulations pharmaceutiques à charge médicamenteuse élevée comprenant de la dronédarone et des sels pharmaceutiquement acceptables de celles-ci
WO2010038091A3 (fr) Composition pharmaceutique a combinaison stable
WO2011056785A3 (fr) Compositions de cellulose microcristalline et de phosphate de calcium utiles en tant qu'excipients pharmaceutiques
JP2011516544A5 (fr)
MY185947A (en) A pharmaceutical composition containing candesartan cilexetil and amlodipine
MA32722B1 (fr) Formulation galénique renfermant de l'aliskirène et procédé associé de préparation par granulation par fusion-extrusion
WO2009008004A3 (fr) Formulations à libération prolongée de divalproex de sodium

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2801020

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11785947

Country of ref document: EP

Kind code of ref document: A2